News
VKTX cayó un 42 % tras decepcionar con su fármaco oral contra la obesidad, generando choque entre analistas optimistas y ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback